Patrick Lin - 15 May 2026 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Reporting relationship: Chief Business - Strategy Off
Issuer ticker: PCSA
Reported as of: 15 May 2026
Net transaction value: +$4,066
SEC form: 4
Accepted by SEC: 19 May 2026, 18:02:07 UTC
Prior SEC filing: 01 May 2026
Next SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact

Key filing fact

Patrick Lin filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 19 May 2026.

Key facts

This page summarizes Patrick Lin's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 19 May 2026, 18:02.

Change

Previous filing in this sequence was filed on 01 May 2026.
Current net transaction value: +$4,066.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001799363 Primary reporting owner

Lin Patrick

Relationship: Chief Business - Strategy Off
Address: C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH
Signature: /s/ Patrick Lin by John J. Wolfel, as Attorney-in-Fact
Signature date: 19 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCSA transaction

Common Stock

Purchase

Transaction value: $4,066
Shares: +1,369
Change %: +22%
Price: $2.97
Shares after: 7,594
Date: 15 May 2026
Ownership: Direct
Footnotes: F1

PCSA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,740
Date: 15 May 2026
Ownership: Lin Family Trust Feb 4, 2024

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 11 shares.